We are live on ! Find out more
VRAX icon

Virax Biolabs

5 hedge funds and large institutions have $57.1K invested in Virax Biolabs in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

177% more capital inflows, than outflows

Capital inflows: $68.4K | Capital outflows: $24.7K

150% more funds holding

Funds holding: 2 → 5 (+3)

1.37% more ownership

Funds ownership: 0.81% → 2.18% (+1.4%)

Holders
5
Holders Change
+3
Holders Change %
+150%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

VRAX Hedge Fund Activity: Q3 2025 in Review

5 of the 7,660 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q3 2025, worth a combined $57.1K — up 99% from $28.6K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new VRAX positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $45.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $24.7K sold.

  • 5 institutional investors held Virax Biolabs (VRAX) as of Q3 2025, up from 2 in Q2 2025.
  • Funds reported $57.1K of Virax Biolabs stock for Q3 2025, up 99% quarter-over-quarter.
  • 4 funds opened new Virax Biolabs positions in Q3 2025 and 1 closed out, a net change of +3 holders.
  • The largest Virax Biolabs buyer in Q3 2025 was HRT Financial, an estimated $45.8K added.
  • The largest Virax Biolabs seller in Q3 2025 was Citadel Advisors, an estimated $24.7K sold.

Based on aggregated 13F filings for Q3 2025.